Month: September 2025

NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) — Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at Bernstein’s 2nd Annual Healthcare Forum on Tuesday, September 23, 2025 at 2:50 p.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/events/. The webcast will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which...

CARMEL, Ind., Sept. 19, 2025 (GLOBE NEWSWIRE) — MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that it will provide topline results from its Phase 2 clinical trial of potential once-weekly canvuparatide for patients with chronic hypoparathyroidism (HP) and host an investor webcast on Monday, September 22. The Company will host a conference call and webcast at 8 am ET on Monday, September 22 to discuss the results from the Avail™ Phase 2 trial. Those who would like to participate may access the live webcast here or dial 1-877-407-0779 (US) or 1-201-389-0914 (international). The live and archived webcast of the call and slide presentation will...

TORONTO, Sept. 19, 2025 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is pleased to announce that it has filed an amended and restated preliminary short form base shelf prospectus (the “Prospectus”) to provide the Company with the flexibility to take advantage of financing opportunities and favourable market conditions, if and when needed, during the 25-month period that the Prospectus, once made final, remains effective (the “Effective Period”). A copy of the Prospectus may be obtained under the Company’s SEDAR+ profile at www.sedarplus.ca. The Prospectus has been filed in each of the provinces and territories in Canada. The...

TYLER, Texas, Sept. 19, 2025 (GLOBE NEWSWIRE) — Southside Bancshares, Inc. (the “Company”) and Southside Bank (the “Bank”), a subsidiary of the Company, has announced the upcoming retirement of Lee Gibson, Chief Executive Officer (“CEO”) and director of the Company and the Bank, effective December 31, 2025. Mr. Gibson will continue as a director of the Company and the Bank. Succeeding him as CEO upon his retirement is Keith Donahoe, current President of the Company and the Bank, who has over 30 years of banking experience. “It goes without saying that Lee has been a vital part of this organization’s success over the last 40-plus years,” said Jay Shands, Chairman of the Board of Southside Bank and Southside Bancshares, Inc. “Starting his career with Southside in 1984, Lee has had a front row seat to a vibrant and often tempestuous...

WARREN, N.J., Sept. 19, 2025 (GLOBE NEWSWIRE) — Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today expressed its gratitude to the U.S. Department of Health and Human Services (HHS), Secretary Robert F. Kennedy, Jr., and the Trump Administration for convening two Long COVID roundtables focused on patient experiences and research. Long COVID continues to affect millions of Americans; according to Yale Medicine, approximately 20 million adults in the U.S. are living with Long COVID, a condition that not only impacts individual health but also carries major economic consequences by keeping people out of the workforce and contributing to significant productivity losses across the nation. Tevogen believes its investigational drug, TVGN 489, which has demonstrated promising results in a Proof-of-Concept clinical...

GRIMSBY, Ontario, Sept. 19, 2025 (GLOBE NEWSWIRE) — Andrew Peller Limited ADW.A / ADW.B (“APL” or the “Company”) announced the final voting results from its 2025 annual general meeting (the “Meeting”) of shareholders held on September 17, 2025. The total number of Class B Voting Shares represented by shareholders present in person or by proxy at the Meeting was 18, representing 76.82% of the 8,036,183 voting shares issued and outstanding as of the record date. 1. Election of Directors – The following six nominees were elected to serve as directors. The nominees and respective term limits were listed in the Company’s management information circular dated August 13, 2025: Nominee # Votes For % Votes For # VotesAgainst % VotesAgainst Brian J. Bidulka 6,156,216  99.72%  17,060  0.28%  Daniel J. Cicerchi 6,161,136  99.80%  12,140  0.20%  Paul...

Company to Highlight Broad Portfolio of Semiconductor and Passive Technologies in a Series of Reference Designs and Product Demos Focused on AI Servers, Smart Cockpits, Vehicle Computing Platforms, and More MALVERN, Pa., Sept. 19, 2025 (GLOBE NEWSWIRE) — Vishay Intertechnology, Inc. (NYSE: VSH) today announced that the company will be showcasing its latest semiconductor and passive technologies at PCIM Asia 2025. In Booth N5, C48, visitors are invited to explore Vishay’s differentiated products and reference designs tailored to the rapidly evolving demands of AI infrastructure and electric vehicles (EV). At PCIM Asia, Vishay’s exhibits will highlight the company’s solutions for server power supplies, DC/DC converters, power delivery units, BBUs, mainboards, and optical modules in AI infrastructure and applications, as well as smart...

SAN JUAN, Puerto Rico, Sept. 19, 2025 (GLOBE NEWSWIRE) — Red Cat Holdings, Inc. (Nasdaq: RCAT) (“Red Cat” or “Company”), a drone technology company integrating robotic hardware and software for military, government, and commercial operations, announced today the pricing of an underwritten public offering of 17,968,750 shares of common stock, including the full exercise of the underwriters’ option to purchase 2,343,750 additional shares on September 19, 2025. The gross proceeds from the offering to the Company were approximately $172.5 million, before deducting underwriting discounts and commissions and other offering expenses. The Company intends to use net proceeds from the offering for general corporate and working capital purposes, including but not limited to operating expenditures related to its new unmanned surface vessel...